Sodium‐glucose co‐transporter 2 inhibitors (SGLT2‐Is) (dapagliflozin, canagliflozin, empagliflozin and ertugliflozin) are the latest therapeutic agents for the treatment of type 2 diabetes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.